(RxWiki News) Teva Pharmaceuticals has suspended sales, marketing and distribution for now for the Zecuity (sumatriptan iontophoretic transdermal system) patch.
Zecuity is used to treat migraines.
Earlier this month, the US Food and Drug Administration (FDA) began investigating the risk of serious burns and scarring associated with the use of Zecuity. Now, the manufacturer has stopped all activity for the migraine treatment to investigate.
The most recent safety communication recommends that physicians discontinue prescribing Zecuity. Furthermore, patients should speak with their health care providers about stopping the use of Zecuity and switching to an alternative treatment for migraines.
Teva has received reports of serious application-site reactions, which range from cracked skin to burns or scars at the location of the application. Other reported side effects include severe redness, blisters and welts.
For additional information, patients can call Migraine Support Solutions at 1-855-ZECUITY (1-855-932-8489).
Patients are encouraged to report adverse events related to Zecuity to Teva at 1-800-896-5855 and to the FDA’s MedWatch Adverse Event Reporting Program.
